Articles and Blogs

FDA

Homeopathic Products Manufacturers Beware – FDA Steps Up Plans for New Enforcement Regime

[10/25/19]

Posted on October 25, 2019 in Health Law News

Published by: Hall Render

The centuries-old practice of homeopathic medicine, which has been the subject of much controversy and debate for nearly the entire length of its existence, may finally be going to the mat with the Food & Drug Administration (“FDA”). Amidst growth in the homeopathic products industry and associated concerns with their safety, efficacy and quality,... READ MORE

Tags: , , , ,

What’s in YOUR Cannabidiol Product Claim? FDA and FTC Want to Know

[10/24/19]

Posted on October 24, 2019 in Health Law News

Published by: Hall Render

It isn’t only the U.S. Food & Drug Administration (“FDA”) and Drug Enforcement Agency (“DEA”) that are interested in all things cannabis. Today, the FDA followed earlier warning letters[1] by posting yet another press release regarding an October 10, 2019 warning letter that was issued jointly by the FDA and the Federal Trade Commission... READ MORE

Tags: , , , , ,

The Practice of Medicine vs. Protecting Patient Safety: Groundbreaking Court Ruling in Support of the FDA’s Regulation of Certain Stem Cell Therapies

[06/11/19]

Posted on June 11, 2019 in Health Law News

Published by: Hall Render

On Monday, June 3, the United States District Court for the Southern District of Florida (the “Court”) ruled that the Food and Drug Administration (“FDA”) has the authority to regulate certain stem cell-based treatments offered by U.S. Stem Cell Clinic, LLC (the “Clinic”) and U.S. Stem Cell, Inc. After the Clinic failed to heed... READ MORE

Tags: , , , , ,

Hall Render’s This Week in Washington – March 8, 2019

[03/08/19]

Posted on March 8, 2019 in Federal Advocacy

Published by: Hall Render

Congress Tackles Health-Related Issues in Multiple Hearings This Week Congress looked at many health policy issues in a week jam-packed with hearings. Continuing Congress’s probe into drug pricing, the House Ways and Means Health Subcommittee held a hearing on promoting competition to lower Medicare prescription drug costs. While lawmakers questioned whether the drug industry... READ MORE

Tags: , , , , , ,

Digital Medicine: OIG Approves Arrangement to Provide Smartphones to Patients

[02/15/19]

Posted on February 15, 2019 in Health Law News

Published by: Hall Render

On January 29, 2019, the Department of Health and Human Services Office of Inspector General (“OIG”) published Advisory Opinion 19-02, which approved an arrangement allowing a pharmaceutical manufacturer to loan smartphones to financially needy patients in order to assist with medication adherence. OIG stated that it would not impose sanctions against the parties for... READ MORE

Tags: , , , , , ,

FDA Clarifies Position on CBD After Passage of 2018 Farm Bill

[01/18/19]

Posted on January 18, 2019 in HR Insights for Health Care

Published by: Hall Render

The United States Food and Drug Administration (“FDA”) issued a statement (the “Statement”) clarifying its position on cannabidiol (“CBD”) products in the wake of the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”) signed December 20, 2018.¹ The 2018 Farm Bill is a broad piece of legislation that regulates agricultural programs ranging from income support... READ MORE

Tags: , , , , , , , ,

FDA Issues New Draft MOU for 503A Compounders Governing Cross-Border Dispensing and Comments Related to CGMP Compliance for Outsourcing Facilities

[11/02/18]

Posted on November 2, 2018 in Health Law News

Published by: Hall Render

On September 7, 2018, the United States Food and Drug Administration (“FDA”) issued a revised draft Memorandum of Understanding (“MOU”) that would govern interstate dispensing and distribution of “inordinate amounts” of compounded prescription drugs by certain compounding physicians and pharmacies. The concept of this MOU first appeared in the Compliance Policy Guidance issued by... READ MORE

Tags: , , , , ,

Department of Homeland Security and FDA Collaborate to Address Medical Device Cybersecurity

[11/02/18]

Posted on November 2, 2018 in Health Law News

Published by: Hall Render

On October 15, 2018, the National Protection and Programs Directorate (“NPPD”) of the U.S. Department of Homeland Security (“DHS”) and the U.S. Food and Drug Administration (“FDA”) entered into a Memorandum of Agreement (“MOA”) that formalizes a long-standing relationship between the agencies and implements a new framework for increased collaboration, information-sharing and coordination that... READ MORE

Tags: , , , , , , , ,

Final FDA Guidance on Interoperable Medical Devices

[09/20/17]

Posted on September 20, 2017 in Health Information Technology

Published by: Hall Render

On September 6, 2017, the U.S. Food and Drug Administration (“FDA”) published final guidance (“Guidance”) summarizing its recommendations for medical devices that are connected to each other and to other technology (“interoperable medical devices”). The Guidance finalizes preliminary guidance from January 2016 and is intended to encourage rapid innovation in the marketplace by allowing... READ MORE

Tags: , ,

FDA Delays New Rule for Off-Label Promotion

[03/23/17]

Posted on March 23, 2017 in Health Law News

Published by: Hall Render

On March 20, 2017, the Food and Drug Administration (“FDA”) published a notice in the Federal Register delaying the implementation of the final rule (“Final Rule”) regulating off-label drug promotion until March 19, 2018. The Final Rule was published in the Federal Register of January 9, 2017. The effective date was originally delayed until... READ MORE

Tags: